A Study of Probiotic Saccharomyces Boulardii and Antibiotic Ciprofloxacin to Prevent Recurrent Urinary Tract Infections in Children

What this Trial Is About

Researchers are studying children aged 2 to 17 years who have recurrent urinary tract infections (UTIs). The trial evaluates a new combination of a probiotic called Saccharomyces Boulardii and the antibiotic ciprofloxacin to prevent repeated UTIs. This early-phase study includes participants with specific urinary tract conditions and excludes those with more severe urinary abnormalities or certain medication interactions to ensure safety. Participants receive 250 mg of the probiotic Saccharomyces Boulardii daily for six months, regardless of symptoms. At enrollment, they are also given ciprofloxacin at a dose of 20 mg/kg. If they have UTI symptoms or a positive urine culture at enrollment, they take ciprofloxacin every 12 hours for 14 days. If they do not have symptoms, ciprofloxacin is only taken at home if a UTI occurs for the first time after enrollment. Standard care for managing recurrent UTIs, including bowel and bladder management, continues throughout the study. During the study, researchers monitor participants for reduction in UTI episodes over six months. Participants receive usual clinical care, and any UTIs caused by bacteria sensitive to ciprofloxacin are treated accordingly. The study tracks safety and effectiveness by assessing UTI recurrence rates and managing any adverse effects. The total participation period includes probiotic treatment and follow-up to evaluate outcomes over half a year.

A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections